Targeted Gut Microbiome Technologies to Drive Transformational Growth Across the Global Healthcare Landscape
This study identifies and analyzes research initiatives focused on the development of gut microbiome therapeutics. Disruption of the gut microbiome causes a range of health issues, including gastrointestinal diseases, immuno-oncological diseases, and metabolic diseases. Over the last decade, gut microbiome therapeutics have largely relied on untargeted approaches, such as fecal microbiome therapy (FMT), probiotics, prebiotics, and synbiotics. However, technological advancements have resulted in the development of and demand for targeted interventions for microbiome therapeutics. Emerging technologies in this space include targeted drugs, cultured commensals, bio-engineered commensals, and bacteriophage therapies. There has been an increase in investments and government funding for the development of gut microbiome therapeutics. The market for gut microbiome therapeutics is expected to see significant growth over the next five years.
Key Questions this Study will Answer:
1. What are the factors driving and restraining the development of gut microbiome therapeutics?
2. What are the venture funding and patent landscapes like for gut microbiome therapeutics?
3. Who are the key industry participants developing gut microbiome therapeutics?
4. What are the clinical trends emerging across each targeted and untargeted approach for the development of gut microbiome therapeutics?
5. What are the key growth opportunities emerging from the shifts in this space? How should market players and stakeholders leverage these opportunities?
Table of Contents
1 Strategic Imperatives
- Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
- The Strategic Imperative 8™
- The Impact of the Top 3 Strategic Imperatives on the Gut Microbiome Market
- Growth Opportunities Fuel the Growth Pipeline Engine™
2 Growth Opportunity Analysis
- Introduction
- Growth Drivers
- Growth Driver Analysis
- Growth Restraints
- Growth Restraints Analysis
- Scope of Analysis
- Segmentation
- Research Methodology
3 Regulatory Landscape
- Regulatory Landscape for Microbiome in Europe
- Regulatory Landscape for Microbiome across the Asia-Pacific
- Regulatory Landscape for Microbiome in North America
- Summary of Global Probiotic Regulations
4 Untargeted Approaches (Clinical Trials Analysis)
- Untargeted Approaches for Treating Oncology Conditions
- Untargeted Approaches for Treating Gastrointestinal Conditions
- Untargeted Approaches for Treating Metabolic Conditions
- Untargeted Approaches for Treating Neurological Conditions
- Untargeted Approaches for Treating Other Conditions
- Analyst Insight - Untargeted Approaches
5 Targeted Approaches (Clinical Trials Analysis)
- Targeted Approaches for Treating Oncology Conditions
- Targeted Approaches for Treating Gastrointestinal Conditions
- Targeted Approaches for Treating Neurological Conditions
- Targeted Approaches for Treating Other Conditions
- Analyst Insights - Targeted Approach
6 Innovation Ecosystem
- Innovation Spotlight in Untargeted Approach
- Innovation Spotlight in Targeted Approach
- R&D Activities (Basic/Applied and Exploratory Research)
- Research Landscape: Analyst Insights
- Increasing Collaborations and Partnerships to Promote the Development of Gut Microbiome Therapeutics
7 IP and Funding
- Patent Landscape for Microbiome Industry
- Significant Venture Capital and Private Equity Funding Boost Innovations in the Gut Microbiome Industry
- Government Grant Funding Supporting Innovations in the Gut Microbiome Industry
8 Growth Opportunity Universe
- Growth Opportunity 1: Gut Microbiome Targeted Approaches
- Growth Opportunity 2: Gut-Brain Axis Applications
- Growth Opportunity 3: Oncological Applications
9 Next Steps
- Your Next Steps
- About the Publisher
- Legal Disclaimer
